Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Obinutuzumab, Lenalidomide, and HDMP in Richter's Syndrome
NCT03113695Phase 1Completed
- Sponsor
- University of California, San Diego
- Start
- Dec 2017
- Primary completion
- May 2022
- Modality
- Antibody Conjugates, Monoclonal Antibodies, Engineered Antibody Formats
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of obinutuzumab and lenalidomide in Richter's syndrome (RS), sponsored by University of California, San Diego. Primary endpoint: Safety and tolerability measured via Adverse Events at 2 years. Started Dec 2017; status: completed.
02
Drugs
obinutuzumablenalidomide
03
Conditions
Richter's syndrome (RS)
Beyond the preview
Go deeper on NCT03113695.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03113695.